Study wrapper · #187
Injectable Peptides in Sports Medicine: A Structured Narrative Review of Evidence, Safety, and Antidoping Implications.
Editor's note
A structured narrative review in a peer-reviewed orthopaedic journal surveying injectable peptides promoted for musculoskeletal recovery. Narrative reviews are synthesis, not new data, and this one is graded Level V (expert synthesis over predominantly low-quality evidence), so it frames the landscape rather than settling any single question. The authors reported that GLP-1 receptor agonists such as semaglutide are the only class here with reproducible randomised evidence of symptomatic improvement in knee osteoarthritis, and that the benefit appears mediated by weight loss and possible anti-inflammatory effects rather than any structural cartilage change, which remains unproven. Crucially, the review places the regenerative and growth-hormone-axis peptides, BPC-157, thymosin derivatives, CJC-1295, ipamorelin and tesamorelin, as investigational, with uncertain safety, product-quality concerns and anti-doping restrictions. Its bottom line is restraint: outside approved metabolic agents for their indicated uses, injectable peptides in sports medicine remain experimental and warrant counselling on uncertain efficacy and contamination and doping risks.
Plain-language abstract
This review pulled together human and lab-based research from 2020 to 2025 on injectable peptides marketed for muscle, joint and tissue recovery in sports medicine. It is a structured summary of existing studies, not new research, and the authors rated the underlying evidence as generally weak. They sorted the peptides into five groups. Only GLP-1 receptor agonists such as semaglutide had repeatable randomised-trial evidence of easing symptoms, specifically in knee osteoarthritis, and that benefit seemed to come mainly from weight loss and possible anti-inflammation rather than from rebuilding cartilage, which was not shown. Collagen-based injections showed early, limited signs of helping recovery after surgery in small single-centre studies. The so-called regenerative peptides (such as BPC-157 and thymosin derivatives) and growth-hormone-boosting peptides (such as CJC-1295, ipamorelin and tesamorelin) were described as still experimental, with unclear safety, concerns about product quality and contamination, and widespread bans in competitive sport. The authors concluded that most injectable peptides for sports use remain experimental, that use should be limited to approved medicines for approved conditions or to proper research, and that athletes should be counselled about uncertain benefit, quality and anti-doping risks.